IRX-5183 is under clinical development by Io Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IRX-5183’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRX-5183 is under development for the treatment of acute myeloid leukemia and multiple myeloma. It is administered orally. The drug candidate is a derivative of vitamin A. Retinoids mediates a number of physiological pathways through their effects on cellular growth and differentiation. It acts by targeting RARalpha. It was also under development for the treatment of solid tumors, acute promyelocytic leukemia and acute myelocytic leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myeloproliferative neoplasms and autoimmune disorders such as encephalomyelitis
Io Therapeutics overview
Io Therapeutics is a biopharmaceutical company that discovers and develops therapeutic compounds. The company develops therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative and auto-immune diseases including multiple sclerosis. Its pipeline products include IRX4204, is an orally available second generation selective RXR agonist against a variety of human cancers in vitro and in animal models including prostate, breast, pancreases and lung; and IRX5183, for the treatment of cancer indications. It offers services in areas of medicinal chemistry and pharmacology. Io Therapeutics is headquartered in Santa Ana, California, the US.
For a complete picture of IRX-5183’s drug-specific PTSR and LoA scores, buy the report here.